Table 4.
Comparison of costs for the no-test and test (sFlt-1/PlGF) strategies and difference in total and per patient costs.
| Service | No-test strategy | Test strategy | Difference (€) | ||
|---|---|---|---|---|---|
| N | Cost (€) | N | Cost (€) | ||
| Initial consultation | 6084 | 3,228,220 | 6084 | 3,228,220 | — |
| Outpatient care | |||||
| Low | 1655 | 13,068,335 | 2185 | 17,248,215 | +4,179,880 |
| Intermediate | 1655 | 17,452,138 | 2498 | 26,666,335 | +9,214,197 |
| Intermediate (after hospitalization) | 1613 | 22,116,244 | 580 | 8,611,745 | –13,504,499 |
| Hospitalization | |||||
| Suspected preeclampsia with birth | 583 | 4,906,013 | 380 | 3,191,864 | –1,714,150 |
| Preeclampsia after ambulatory care | 577 | 5,698,412 | 442 | 4,560,054 | –1,138,357 |
| Total medical costs | 6084 | 66,469,362 | 6084 | 63,506,433 | –2,962,929 |
| sFlt-1/PlGF evaluation | 0 | — | 6084 | 856,627 | +856,627 |
| Overall costs | |||||
| Total | 6084 | 66,469,362 | 6084 | 64,363,060 | –2,106,301 |
| Per patient | 6084 | 10,925 | 6084 | 10,579 | –346 |
PlGF: placental growth factor; sFlt-1: soluble fms-like tyrosine kinase-1.